Introduction
Randomized controlled trials (RCTs) provide the best evidence to support the efficacy and safety of therapies and form the basis for regulatory approval of treatment for all diseases, including chronic obstructive pulmonary disease (COPD). A well-designed RCT has a high degree of internal validity and allows for data-driven determination of whether a cause-effect relationship exists between a study drug and its outcome. Patient populations in RCTs are subject to stringent inclusion and exclusion criteria, [7] [8] [9] [10] [11] [12] Based on the ongoing scientific discussion around the external validation of RCTs, [13] [14] [15] we sought to understand how representative the patients included in RCTs are to patients in a real-life clinical setting, and how the inclusion and exclusion criteria implemented for these trials may have influenced the recruited patient population. In particular, it is important to know whether patients with comorbidities are adequately represented in clinical trials of COPD, or whether they are deselected by exclusion criteria -or simply not recruited in sufficient numbers. To achieve this goal, we surveyed a database of patients recruited into tiotropium RCTs and also conducted a systematic literature review of large-scale observational studies in order to compare the demography and baseline characteristics of the RCT population with "real-life" patient populations.
Methods

analysis of tiotropium rCTs
Data on patient baseline characteristics were taken from a database ( (Table S1 ).
Statistical analysis was based on descriptive characterization of the pooled trials.
Design of the rCTs in the analysis
Studies were randomized, placebo-controlled, double-blind, parallel-group trials of 4 weeks' duration, assessing either tiotropium HandiHaler ® 18 µg (once daily) or tiotropium Respimat ® 5 µg (two puffs of 2.5 µg once daily) for the indication of COPD. Written informed consent was obtained from all patients and ethics committee approval was obtained for all protocols. As all trials were part of the tiotropium COPD development program, inclusion and exclusion criteria were similar across all trials. However, later trials were modified to have somewhat broader selection criteria (see inclusion and exclusion criteria). Principal patient characteristics like age, sex, anthropometrics, and ethnicity were recorded for all patients at baseline. Lung function (as measured by forced expiratory volume in 1 second [FEV 1 ]) and smoking history were also captured for the entire population.
Inclusion criteria of the rCTs in the analysis
The key inclusion criteria common to all tiotropium trials were: diagnosis of COPD, FEV 1 /forced vital capacity ratio 70%, age 40 years, and 10 pack-years' smoking history. Other inclusion criteria such as FEV 1 cutoffs and requirement for exacerbation history varied between studies.
exclusion criteria of the rCTs in the analysis
The key exclusion criteria were: diagnosis of asthma, symptomatic prostatic hypertrophy or bladder neck obstruction, narrow-angle glaucoma, and known hypersensitivity to the study medication or components. For practical reasons, significant disease other than COPD that could significantly confound the study results or preclude study completion was also an exclusion criterion. Other exclusion criteria in earlier trial protocols were: heart failure resulting in hospitalization in the previous 3 years, cardiac arrhythmia requiring drug treatment, or myocardial infarction (MI) within the past year. Nevertheless, heart failure and ischemic heart disease were not necessarily exclusion criteria. Cardiac exclusion criteria were more liberal in more recent trials such as UPLIFT (Table S1 ). Drug therapy for arrhythmias was permitted, provided the therapy was stable and the patient had no history of a life-threatening arrhythmia or pacemaker insertion. In addition, the criterion for recent MI was decreased to 6 months. Use of theophylline, inhaled corticosteroids, 10 µg daily doses of oral corticosteroids (provided the dosing was stable), and short-acting β 2 -agonists was permitted in all trials. The 4-year UPLIFT ® trial (5,992 patients), 16 
Definitions of comorbidities
The Medical Dictionary for Regulatory Activities (MedDRA) version 14.0 was used to code relevant medical history/ concomitant diagnoses (within the past 5 years) as reported by the investigator at baseline; preferred terms (PTs) were categorized under system organ classes (SOCs) within Med-DRA. For conditions that are known to have a high prevalence in patients with COPD, MedDRA PTs denoting similar conditions were pooled as pharmcovigilance (PV) endpoints and Standardised MedDRA Queries (SMQs). Figure 1 . The inclusion criteria for the literature search did not specify how patient demography and comorbidity data were presented. It was only important that this information be reported. For this reason, the number of studies used for the individual analyses will vary.
Results
In total, 17,990 and 6,565 patients were included in the HandiHaler ® and Respimat ® trials, respectively. For the systematic literature search, using the search parameters detailed in the "Methods" section, 806 study publications were returned. Following a secondary screen to exclude all studies reporting RCTs, hospitalized patient populations, age-restricted populations, or reported study populations of fewer than 900 patients, 793 studies were excluded and 13 epidemiological and observational studies 12, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (n=61,361 patients) were included for comparison with the anthropometrics of patients with COPD recruited in tiotropium RCTs (Table S2) .
Baseline demographics and clinical characteristics
The baseline demographics (Table 1) Table 2 ).
Although all of the observational studies reported baseline comorbidities in the patient population, they differed in how this was reported. In some instances, these were reported either by SOC or PT. The observational studies also differed in the level of additional information reported, relating to patient baseline characteristics and baseline concomitant medications. For this reason, the numbers of studies included in the comparisons of these parameters differ in Tables 2-4 .
Baseline comorbidities
The majority of patients in the HandiHaler ® and Respimat ® trials were diagnosed with comorbidities at baseline (79.4% and 74.2%, respectively), with vascular and cardiac disorders being the most frequent (39.3% and 24.6% in the HandiHaler ® trials, respectively, and 40.1% and 24.3% in the Respimat ® trials, respectively) ( Table 3 ). The incidence of comorbidities was similar between the placebo and tiotropium treatment groups in both sets of trials. In four observational studies that enrolled a total of 17,048 patients with COPD, associated comorbidities grouped by SOC 
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Miravitlles et al included cardiac (9.4%-32.3%), vascular (11.4%-45.0%), metabolic and nutritional (9.9%-22.2%), and psychiatric (11.9%) disorders (Table 3) .
For comorbidities that are known to have a high prevalence in patients with COPD (hypertension, ischemic heart disease, dyslipidemia, diabetes, anxiety, and depression), SMQs or PV endpoints were used for the RCTs and applicable PTs were grouped to combine endpoints for observational studies in order to evaluate their prevalence in study populations at baseline (Table 4 and Table S3 ). 
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Baseline patient characteristics in tiotropium COPD trials (Table 4) .
When reported by applicable PTs, the comorbidities with the highest prevalence in epidemiological and observational studies were hypertension (40.1%-60.6%), cardiac arrhythmia (11.3%-15.8%), depressed mood (17.0%-20.6%), cardiac failure (7.0%-49.0%), and ischemic heart disease (12.5%-41.0%, Table 4 ). In UPLIFT ® , increases in comorbid conditions from baseline to year 4 were observed (Table S4 ).
Discussion
We have analyzed the demographic data of patients in randomized, placebo-controlled clinical studies with tiotropium HandiHaler ® and Respimat ® of at least 4 weeks' duration and compared these with data from epidemiological and observational studies. The background for this comparison was that, recently, several authors questioned the validity of RCTs for the evaluation of the safety of drugs in the treatment of COPD in clinical practice. 13, 14 The pivotal argument for these concerns was that the inclusion and exclusion criteria of RCTs prevent patients at greater risk (notably of cardiovascular [CV] risk) from participating in these studies. This could then potentially lead to a more positive safety evaluation of the drugs in question compared with clinical practice in a real-life setting.
This study of the characteristics of the 24,555 patients included in the randomized trials of tiotropium showed that the clinical profile, including age, sex, smoking history, and anthropometrics of these patients, is similar to that observed in large epidemiological and observational studies of patients with COPD. However, the proportions of patients with mild to moderate disease (GOLD stages I+II) ranged from 24.5% to 44.1% in the observational studies but from 40.0% to 51.5% in the tiotropium trials, while patients with severe disease (GOLD stage III or IV) were represented in similar numbers in the tiotropium RCTs (7.2%-45.8%) as in the observational studies (13.7%-42.1%).
Comorbidities
The most prevalent comorbidities reported by SOC observed in the COPD patient population at baseline in the pooled tiotropium trials were: cardiac, vascular, respiratory, gastrointestinal, psychiatric, and metabolic disorders. These were represented in the observational studies in similar proportions (Table 3 ). In particular, the prevalence of cardiac disorders in the 22,916 evaluable patients in the tiotropium RCT population was 24.3%-24.6%. Of the 17,048 patients with COPD in the epidemiologic/observational studies, 21, 25, 26, 30 the prevalence of cardiac disorders was in the range of 9.4%-32.3%. In a recent letter to the editor, 39 the authors conducted an audit of patients discharged from hospital in New Zealand after an exacerbation of COPD and found that 38% patients prescribed tiotropium had comorbidities that would have made them ineligible for participation in UPLIFT ® . Based on this observation, the authors concluded that the findings from UPLIFT ® had limited generalizability to clinical practice in New Zealand. However, this New Zealand patient population is a very severe population of patients that required hospital admission, whereas patients included in UPLIFT ® , as in all major clinical trials of COPD, consisted of ambulatory patients. The pattern of comorbidities of very severe admitted patients may differ, but this New Zealand patient population represents a minority of patients with COPD of special severity with increased risks of side effects secondary to all drugs and that require a personalized approach with careful evaluation of the expected benefits and risks of any given treatment.
Although it was excluded from our systematic literature review because it is a pooled analysis of epidemiological studies, validation of the current analysis is provided by a study conducted by Patel and Hurst. 40 Using data from two large, population-based epidemiological studies (the Atherosclerosis Risk in Communities [ARIC] Study and the Cardiovascular Health Study [CHS], 20,296 adults aged 44 years), 40 they reported that the prevalence of CV disease (defined as a composite of ischemic heart disease, heart failure, stroke, and/or transient ischemic attack) in patients with COPD was 20.0%-22.0%. This is similar to the 24.6% and 24.3% prevalence of cardiac disorders that we determined in the tiotropium trials. This contradicts the concerns that the inclusion and exclusion criteria of tiotropium RCTs prevent patients at greater risk (notably of CV risk) from participating in these studies.
Comorbidities of interest were selected on the basis of being the most frequently reported in COPD trials and also to maximize the degree of comparisons with the observational studies identified in our systematic literature review. For eight selected comorbidities of interest (Table 4) , our analysis revealed that hypertension had the highest prevalence in patients enrolled in tiotropium RCTs (39.4%-40.0%).
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Baseline patient characteristics in tiotropium COPD trials This was lower than the range (51.4%-60.6%) reported in four out of nine observational studies 26, 28, 32, 35, 36 (total: 6,884 patients) used in our comparison. However, in a populationbased National Institutes of Health cohort of 20,296 patients with COPD aged 45 years, the prevalence of hypertension was 40.1%, 32 similar to that reported for patients in tiotropium RCTs.
Although not included in our current analysis because it is not among the most frequently reported comorbidities among patients with COPD, two reports, by Verhamme et al 41 (Table S5) . 43 limitations of the study A major limitation of this study is the difference in the reporting of baseline characteristics and comorbidities in the observational studies identified in our systematic literature review. Only six of the observational studies reported the GOLD staging of patients. Although included in this comparison, Mannino et al's study 32 reports GOLD staging for only 27.1% of the patients enrolled, which complicates interpretation of these results. Furthermore, four studies reported baseline comorbidities by SOC, and none of these allowed for a full comparison with the tiotropium RCTs. This means that for comorbidities such as respiratory, thoracic and mediastinal disorders, gastrointestinal disorders, psychiatric disorders, and neoplasms, the patient population against which the tiotropium RCT population is compared is limited (only 2,846 from two of the four observational studies as compared with 22,916 in the tiotropium RCTs combined). This variability complicates interpretation of these results due to the limited sample size. Although this situation is repeated for comparison of baseline comorbidities in Table 4 , it is mitigated to some extent by the inclusion of 51,050 patients from nine out of 13 observational studies for comparison to the 22,916 patients identified in the included tiotropium RCTs.
Another limitation of this study is that it does not take into account the various factors that add to the complexity of studying comorbidities in patients with COPD. These include: smoking status, which has been shown to be a risk factor for diabetes mellitus and dyslipidemia; age; polypharmacy; lack of treatment of comorbidities; and lack of specific case definitions for comorbidities. 7 However, with regard to smoking status, the percentage of current smokers enrolled in the tiotropium RCTs is similar to the percentage identified as current smokers in the observational studies included in our analysis.
Lastly, patients with recent unstable cardiac diseases (MI within 6 months and new unstable arrhythmia or severe heart failure within 1 year) were excluded from the tiotropium RCTs. Therefore, the findings in the tiotropium studies cannot be extended to these patients.
Conclusion
The clinical profile (defined by SOC) of patients with COPD treated in the tiotropium trial program appears to be largely in the range of clinical characteristics, including CV comorbidities reported for "real-life patients." Overall, patients in the tiotropium studies were comparable to those patients enrolled in the observational studies with regard to the severity of disease (GOLD stages III and IV).
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Baseline patient characteristics in tiotropium COPD trials Chronic obstructive pulmonary disease as a cardiovascular risk factor. results of a case-control study (COnsIsTe study)
970
The study cohort was recruited from primary and specialized care consultations in spain. COPD patients were recruited when they attended the clinic for a routine check-up.
de lucas-ramos P et al 33 The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from nhanes The population-based cohort included in this study were patients with COPD 55 years old receiving a first treatment for COPD between 1990 and 1997 in saskatchewan, Canada, and were part of the saskatchewan health Databases.
huiart l et al 40 heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study
1,927
The GPRD was used to identify a cohort of 1927 patients with a first recorded diagnosis of COPD. subjects were followed for up to 5 years to identify new diagnoses of lung cancer, MI and heart failure. 
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Baseline patient characteristics in tiotropium COPD trials to 60 ml/min, severe 30 ml/min creatinine. The Irr could not be calculated for severe renal impairment due to low patient numbers.
#
The same patients may fulfill criteria for inclusion in different AE categories. Hence, numbers are not additive. *If there are no events in the placebo or tiotropium group, IRRs cannot be calculated (division by zero) or are equal to zero, respectively; the incident rates for tiotropium/placebo are presented instead. Abbreviations: Fae, fatal adverse event; MaCe, major adverse cardiovascular event; nICe, national Institute for health and Care excellence; sae, serious adverse event; sOC, system organ class.
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